Gene transfer to airway and alveolar epithelial cells in vivo continues to offer hope as a therapeutic approach for genetic diseases such as cystic fibrosis (CF), as a pharmaceutical delivery technique for acute and acquired lung injuries, and as a powerful research tool. However, successful and sustained gene expression in the epithelium has often been limited by factors associated with effective vector delivery, particularly in injured or diseased lungs; innate inflammatory and immune responses to vectors; and longevity of gene expression.

One hypothetical means of overcoming the last limitation would be to target endogenous progenitor cells in the lung, cells that would subsequently provide sustained and widespread gene expression in the daughter cells arising from the progenitor-cell populations. However, specific targeting of endogenous airway progenitor cells has not previously been described.

It is in this context that the timely and important work of Liu and colleagues in this issue of Molecular Therapy elegantly demonstrates that recombinant adenoviral vectors, notably AAV1 and AAV5, seem to preferentially transduce progenitor cells in the lower airways in mice. This exciting and new finding provides an important platform for specifically targeting airway progenitor cells and raises hope that, once duplicated in humans, this approach may someday be used in clinical gene therapy attempts in CF and other lung diseases.

Endogenous tissue stem cells are undifferentiated cells that have been identified in nearly all tissues, including lung, and are thought to contribute to tissue maintenance and repair. These rare, highly specialized cells are often localized to specialized niches within each tissue and not only can self-renew, although they usually cycle infrequently, but also can give rise to more daughter cells known as progenitor cells or transit-amplifying cells. Both stem and progenitor cells may give rise to the more specialized, or differentiated, cells of the organ. The focus in lung has been predominantly on epithelial progenitor cells, but increasing evidence indicates the potential existence of vascular and mesenchymal progenitor cell populations as well. Moreover, because the lung is a complex organ, several airway epithelial stem and progenitor-cell hierarchies have been identified along the tracheobronchial tree in mouse models (Figure 1). In trachea and large airways, a subpopulation of basal epithelial cells that express cytokeratins 5 and 14 has been implicated. Another population of naphthalene-resistant Clara cells, BASCs, and other cells may represent different interpretations of the same cell population(s); this both highlights the need for rigorous methods of lineage tracing and further underscores the importance of the in vivo microenvironment in cell behavior. Most recently, another population of putative progenitor cells expressing CCSP, stem cell antigen 1, stage-specific embryonic antigen 1, and the embryonic stem cell marker Oct-4 have been identified in neonatal mice. These cells were able to form epithelial colonies and differentiate into both type 1 and type 2 alveolar epithelial cells. Interestingly, these cells were susceptible to infection with the severe acute respiratory syndrome (SARS) virus, raising the possibility that endogenous lung progenitor cells may be specific disease targets. The possibility remains that other endogenous stem or progenitor populations exist, and there is much room for additional information on the regulatory mechanisms and pathways that have been elucidated in other epithelial progenitor cell populations (reviewed in refs. 3–5, 14). The human correlates of the endogenous airway progenitor populations described in mice are less well understood. Defining human airway progenitor populations is a critical step and the focus of intense research activity.

Endogenous progenitor cells may also be attractive candidates for targeting with gene transfer vectors that provide sustained expression. Using adult transgenic Rosa26-Flox/LacZ reporter mice, Liu and colleagues demonstrated that airway-based administration of recombinant rAAV1 and rAAV5 Cre
vectors preferentially transduced type 2 alveolar epithelial cells and cells in the conducting but not larger airways. Notably, the number of β-gal-expressing conducting airway cells, predominantly Clara cells, and overall amount of β-gal activity in lung homogenates steadily increased over a 6-month period, reaching, respectively for rAAV1 Cre and rAAV5 Cre, 3% and 5% of total activity measured in positive control Rosa26-LacZ reporter mice—despite the absence of detectable Cre in Clara cells. Speculating that this might result in part from rAAV-mediated transduction of airway progenitor cells, the investigators administered naphthalene to the Rosa26-LacZ reporter mice and demonstrated larger LacZ-positive cell clusters, again suggestive of clonal expansion of the rAAV-Cre–transduced Rosa26-Flox/LacZ mice despite the absence of detectable Cre in Clara cells postnatally. This suggests that endogenous progenitor cell pathways in CF lungs may be altered and are potentially amenable to selective transduction by rAAV or other vectors. Whether other lung diseases prove amenable to these approaches remains to be determined. Furthermore, despite a growing understanding of the identities and roles of airway endogenous lung stem/progenitor cells in mice, there is little comparable information available for the human lung. Nonetheless, the union of gene and cell therapies holds promise for lung diseases.

REFERENCES

1. Sueblinvong, V, Suratt, BT and Weiss DJ (2007). Novel therapies for the treatment of cystic fibrosis: new developments in gene and stem cell therapy. Clin Chest Med 28: 361–379.
2. Liu, X, Luo, M, Guo, C, Yan, Z, Wang, Y, Lei-Butters, DCM et al. (2009). Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther 17: 285–293.
3. Rawlins, EL and Hogan, BL (2006). Epithelial stem cells of the lung: privileged few or opportunities for many? Development 133: 2455–2465.
4. Stripp, BR (2008). Hierarchical organization of lung progenitor cells: is there an adult lung tissue stem cell? Proc Am Thoracic Soc 5: 695–698.
5. Kim, CF (2007). Paving the road for lung stem cell biology: bronchioalveolar stem cells and other putative distal lung stem cells. Am J Physiol Lung Cell Mol Physiol 293: L1092–L1098.
6. Borthwick, DW, Shahbazian, M, Kranitz, QT, Dorin, JR and Randell, SH (2001). Evidence for stem-cell niches in the tracheal epithelium. Am J Respir Cell Mol Biol 24: 662–670.
7. Schoch, KG, Lori, A, Burns, KA, Eldred, T, Olsen, JC and Randell, SH (2004). A subset of mouse tracheal...
epithelial basal cells generates large colonies in vitro. Am J Physiol Lung Cell Mol Physiol 286: L631–L642.

8. Engelhardt, JE, Schlossberg, H, Yankaskas, JR and Dudus, L (1995). Progenitor cells of the adult human airway involved in submucosal gland development. Development 121: 2031–2046.

9. Avril-Delplanque, A, Casal, I, Castillon, N, Hinrrasky, J, Puchelle, E and Peault, B (2005). Aquaporin-3 expression in human fetal airway epithelial progenitor cells. Stem Cells 23: 992–1001.

10. Giangreco, A, Reynolds, SD and Stripp, BR (2002). Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 161: 173–182.

11. Hong, KU, Reynolds, SD, Giangreco, A, Hurley, CM and Stripp, BR (2001). Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 24: 671–681.

12. Kim, CF, Jackson, EL, Woollfenden, AE, Lawrence, S, Babar, I, Vogel S et al. (2005). Identification of bronchoalveolar stem cells in normal lung and lung cancer. Cell 121: 823–835.

13. Ling, TY, Kuo, MD, Li, CL, Yu, AL, Huang, YH, Wu, TJ et al. (2006). Identification of pulmonary Oct-4 stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci USA 103: 9530–9535.

14. Weiss, DJ, Kolls, JK, Ortiz, LA, Panoskaliis-Mortari, A and Prockop, DJ (2008). Stem cells and cell therapy approaches for lung diseases. Conference report. Proc Am Thoracic Soc 5: 637–647.

15. Hollande, E, Cantet, S, Ratovo, G, Daste, G, Bremont, F and Fanjul, M (2004). Growth of putative progenitors of type II pneumocytes in culture of human cystic fibrosis alveoli. Biol Cell 96: 429–441.

16. Pan, J, Luk, C, Kent, G, Cutz, E and Yeger, H (2006). Pulmonary neuroendocrine cells, airway innervation, and smooth muscle are altered in Cfr null mice. Am J Respir Cell Mol Biol 35: 320–326.

See page 369

Casting Doubt on the Safety of “Off-the-shelf” Mesenchymal Stem Cells for Cell Therapy

Pranela Rameshwar

doi:10.1038/mt.2008.296

Mesenchymal stem cells (MSCs) show promise for gene delivery to treat various diseases such as anemia and stroke, as well as other oncological and neural disorders. In this issue of Molecular Therapy, Campeau et al. report on an experimental model that compares the responses of allogeneic and syngeneic hosts to the transfer of erythropoietin (EPO)-expressing MSCs. The studies were based on the premise that EPO could be delivered using genetically modified MSCs to treat anemia or myocardial infarction. The treatment of anemia with expanded autologous MSCs seems plausible, in that the chronic nature of anemia is compatible with the time needed to expand bone marrow–derived MSCs to sufficient numbers. However, in the case of acute disorders such as myocardial infarction and stroke, gene delivery interventions would have to be immediate, thereby eliminating autologous gene-modified MSCs as an option. Because MSCs have been reported to suppress allogeneic responses, in particular graft-versus-host disease, “off-the-shelf” sources of such cells have been proposed to treat various clinical disorders that require intervention at early time points.

Allogeneic MSCs are already being evaluated in the clinic to treat graft-versus-host responses and other autoimmune disorders. These treatments are based on the immunosuppressive properties of MSCs. MSCs, as third-party cells in the allogeneic hematopoietic stem cell transplantation setting, can function as immunosuppressive cells. Similar immunosuppression would not be relevant in autologous transplantation where rejection would not be a problem. Despite this promise of MSCs as third-party cells, this type of application is different from the delivery of MSCs to an allogeneic host to deliver a therapeutic gene, such as EPO. Because the delivery of allogeneic MSCs has been reported only relatively recently, it is difficult to verify their safety in allogeneic hosts, such as their use as cellular vectors for gene delivery. Thus, the safety of the use of MSCs for therapeutic gene transfer remains to be established.

Campeau et al. now report unexpected phenotypic and immunological effects following the delivery of allogeneic MSCs engineered to express EPO into mice of different haplotypes: BALB/c and C57BL/6 (Figure 1). MSCs from C57BL/6 mice were engineered to express EPO using a retroviral system. The engineered cells were then injected subcutaneously into healthy syngeneic C57BL/6 mice and allogeneic BALB/C mice. In both cases there were transient increases in hematocrit. Although the baseline level of EPO was maintained following cell transfer in the syngeneic transplants, hematocrit levels soon decreased below baseline levels in the allogeneic transplants. The allogeneic mice showed rapid increases in antibodies against EPO (anti-EPO), whose levels were sustained for at least 7 weeks. In contrast, there was a gradual increase in anti-EPO levels in the syngeneic animals. At week 12 the significant differences in hematocrit levels between the two strains of mice could not be explained by differences in anti-EPO levels. The authors further explored this paradox by determining whether there were differences between the neutralizing abilities of the anti-EPOs in the two strains of mice. Using an EPO-responsive cell line, the authors compared the neutralization properties of anti-EPO in the sera of both strains of treated mice. Although anti-EPO from the allogeneic sera was able to neutralize EPO, the sera from the syngeneic sera showed only partial neutralization, suggesting differences in the avidity of the antibodies.

To further understand the mechanism by which EPO expression induced anti-EPO in the allogeneic mice, the authors analyzed the MSCs for cytokine secretion. The major upregulated cytokine in the EPO-engineered MSCs, C-C motif chemokine 2, did not show evidence of involvement in the anti-EPO response, suggesting other mechanisms and/or involvement of other cytokines.